Aprea Therapeutics (APRE) Free Cash Flow Growth (3y) (2021 - 2026)
Aprea Therapeutics (APRE) Free Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -1.95% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -20.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 21.16% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 45.09% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 80.69% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -23.92% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 8.92% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -4.45% |
| 10 | Aprea Therapeutics | 34.25 Mn | 34.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.64% |
| Mar 31, 2026 | 2.55% |
| Dec 31, 2025 | 9.69% |
| Sep 30, 2025 | 21.65% |
| Jun 30, 2025 | 29.42% |
| Mar 31, 2025 | 12.90% |
| Dec 31, 2024 | 29.87% |
| Sep 30, 2024 | 33.07% |
| Jun 30, 2024 | 22.21% |
| Mar 31, 2024 | 30.05% |
| Dec 31, 2023 | 34.31% |
| Sep 30, 2023 | 41.89% |
| Jun 30, 2023 | 30.63% |
| Mar 31, 2023 | 26.67% |
| Dec 31, 2022 | 35.17% |
| Sep 30, 2022 | -32.98% |
| Jun 30, 2022 | -21.40% |
| Mar 31, 2022 | -9.40% |
| Dec 31, 2021 | -38.27% |